Styczyński, Jan 
; Tridello, Gloria ; Xhaard, Alienor ; Medinger, Michael ; Mielke, Stephan ; Taskinen, Mervi ; Blijlevens, Nicole ; Rodriguez, M. Aranzazu Bermudez ; Solano, Carlos ; Nikolousis, Emmanouil ; Biffi, Alessandra ; Groll, Andreas H. ; Junghanss, Christian ; Tsirigotis, Panagiotis ; Lioure, Bruno ; Šrámek, Jiří ; Holler, Ernst ; Galaverna, Federica ; Fagioli, Franca ; Knelange, Nina ; Wendel, Lotus ; Gil, Lidia ; de la Camara, Rafael ; Mikulska, Malgorzata ; Ljungman, Per
; Tridello, Gloria ; Xhaard, Alienor ; Medinger, Michael ; Mielke, Stephan ; Taskinen, Mervi ; Blijlevens, Nicole ; Rodriguez, M. Aranzazu Bermudez ; Solano, Carlos ; Nikolousis, Emmanouil ; Biffi, Alessandra ; Groll, Andreas H. ; Junghanss, Christian ; Tsirigotis, Panagiotis ; Lioure, Bruno ; Šrámek, Jiří ; Holler, Ernst ; Galaverna, Federica ; Fagioli, Franca ; Knelange, Nina ; Wendel, Lotus ; Gil, Lidia ; de la Camara, Rafael ; Mikulska, Malgorzata ; Ljungman, Per 
Zusammenfassung
Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the approved indication. The objective of the study was to analyze the efficacy and safety of the use of LMV in off-label indications in EBMT centers. A ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric